Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Shaji Kumar, Edward A. Faber, Adam D. Cohen, Natalie Scott Callander, Avina A. Singh, Terri L. Parker, Alex R. Menter, Xuezhong Yang, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Rosenberg Aaron, Jeffrey A. Zonder, Kenneth Carl Anderson, Sagar Lonial, Paul G. Richardson, Robert Z. Orlowski, Lynne I. Wagner, S. Vincent Rajkumar, Susanna J. Jacobus
Institutions: Mayo Clinic, University of Cincinnati, Abramson Cancer Center, University of Pennsylvania, University of Wisconsin Carbone Cancer Center, University of Wisconsin Health, Minnesota Oncology, Yale University, Kaiser Permanente, Kaiser Permanente Lone Tree Medical Offices, Bon Secours Health System, Gundersen Health System, Illinois CancerCare, University of California, Davis, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Emory University Hospital, Winship Cancer Institute, The University of Texas MD Anderson Cancer Center, University of North Carolina at Chapel Hill
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410809873